Literature DB >> 28378243

Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.

V Prendki1, T Ferry2, P Sergent3, E Oziol4, E Forestier5, T Fraisse6, S Tounes7, S Ansart8, J Gaillat9, S Bayle10, O Ruyer11, F Borlot11, G Le Falher11, B Simorre11, F-A Dauchy12, S Greffe13, T Bauer14, E N Bell15, B Martha16, M Martinot17, M Froidure18, M Buisson19, A Waldner20, X Lemaire21, A Bosseray22, M Maillet23, V Charvet24, A Barrelet25, B Wyplosz26, M Noaillon27, E Denes28, E Beretti29, M Berlioz-Thibal30, V Meyssonnier31, E Fourniols32, L Tliba33, A Eden34, M Jean34, C Arvieux35, K Guignery-Kadri36, C Ronde-Oustau37, Y Hansmann38, A Belkacem39, F Bouchand40, G Gavazzi41, F Herrmann42, J Stirnemann43, A Dinh44,45,46.   

Abstract

During prosthetic joint infection (PJI), optimal surgical management with exchange of the device is sometimes impossible, especially in the elderly population. Thus, prolonged suppressive antibiotic therapy (PSAT) is the only option to prevent acute sepsis, but little is known about this strategy. We aimed to describe the characteristics, outcome and tolerance of PSAT in elderly patients with PJI. We performed a national cross-sectional cohort study of patients >75 years old and treated with PSAT for PJI. We evaluated the occurrence of events, which were defined as: (i) local or systemic progression of the infection (failure), (ii) death and (iii) discontinuation or switch of PSAT. A total of 136 patients were included, with a median age of 83 years [interquartile range (IQR) 81-88]. The predominant pathogen involved was Staphylococcus (62.1%) (Staphylococcus aureus in 41.7%). A single antimicrobial drug was prescribed in 96 cases (70.6%). There were 46 (33.8%) patients with an event: 25 (18%) with an adverse drug reaction leading to definitive discontinuation or switch of PSAT, 8 (5.9%) with progression of sepsis and 13 died (9.6%). Among patients under follow-up, the survival rate without an event at 2 years was 61% [95% confidence interval (CI): 51;74]. In the multivariate Cox analysis, patients with higher World Health Organization (WHO) score had an increased risk of an event [hazard ratio (HR) = 1.5, p = 0.014], whereas patients treated with beta-lactams are associated with less risk of events occurring (HR = 0.5, p = 0.048). In our cohort, PSAT could be an effective and safe option for PJI in the elderly.

Entities:  

Keywords:  Adverse Drug Reaction; Antimicrobial Therapy; Fusidic Acid; Prosthetic Joint Infection; Sinus Tract

Mesh:

Substances:

Year:  2017        PMID: 28378243     DOI: 10.1007/s10096-017-2971-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

Review 1.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

2.  Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid.

Authors:  C A Aboltins; M A Page; K L Buising; A W J Jenney; J R Daffy; P F M Choong; P A Stanley
Journal:  Clin Microbiol Infect       Date:  2007-02-28       Impact factor: 8.067

3.  Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis.

Authors:  Allison F Messina; Katie Namtu; Michelle Guild; Juan A Dumois; David M Berman
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

4.  Epidemiology of adverse events and Clostridium difficile-associated diarrhea during long-term antibiotic therapy for osteoarticular infections.

Authors:  Maximilian Schindler; Louis Bernard; Wilson Belaieff; Axel Gamulin; Guillaume Racloz; Stéphane Emonet; Daniel Lew; Pierre Hoffmeyer; Ilker Uçkay
Journal:  J Infect       Date:  2013-07-12       Impact factor: 6.072

5.  Outcome of prosthetic joint infections treated with debridement and retention of components.

Authors:  C E Marculescu; E F Berbari; A D Hanssen; J M Steckelberg; S W Harmsen; J N Mandrekar; D R Osmon
Journal:  Clin Infect Dis       Date:  2006-01-05       Impact factor: 9.079

6.  Incidence and short-term outcomes of primary and revision hip replacement in the United States.

Authors:  Chunliu Zhan; Ronald Kaczmarek; Nilsa Loyo-Berrios; Judith Sangl; Roselie A Bright
Journal:  J Bone Joint Surg Am       Date:  2007-03       Impact factor: 5.284

7.  Adverse effects of parenteral antimicrobial therapy for chronic bone infections.

Authors:  C Pulcini; T Couadau; E Bernard; A Lorthat-Jacob; T Bauer; E Cua; V Mondain; R-M Chichmanian; P Dellamonica; P-M Roger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-09-26       Impact factor: 3.267

8.  Prolonged suppression of infection in total hip arthroplasty.

Authors:  J A Goulet; P M Pellicci; B D Brause; E M Salvati
Journal:  J Arthroplasty       Date:  1988       Impact factor: 4.757

9.  Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.

Authors:  Florent Valour; Judith Karsenty; Anissa Bouaziz; Florence Ader; Michel Tod; Sébastien Lustig; Frédéric Laurent; René Ecochard; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

10.  Suppressive antibiotic therapy in chronic prosthetic joint infections.

Authors:  D T Tsukayama; B Wicklund; R B Gustilo
Journal:  Orthopedics       Date:  1991-08       Impact factor: 1.390

View more
  11 in total

1.  Prolonged suppressive antibiotic therapy is successful in the management of prosthetic joint infection.

Authors:  N A Sandiford; J R Hutt; D O Kendoff; P A Mitchell; M Citak; L Granger
Journal:  Eur J Orthop Surg Traumatol       Date:  2019-10-01

2.  Should we expand the indications for the DAIR (debridement, antibiotic therapy, and implant retention) procedure for Staphylococcus aureus prosthetic joint infections? A multicenter retrospective study.

Authors:  O Lesens; T Ferry; E Forestier; E Botelho-Nevers; P Pavese; E Piet; B Pereira; E Montbarbon; B Boyer; S Lustig; S Descamps
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-08-07       Impact factor: 3.267

3.  Salvage Debridement, Antibiotics and Implant Retention ("DAIR") With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection?

Authors:  Tristan Ferry; Gilles Leboucher; Cindy Fevre; Yannick Herry; Anne Conrad; Jérôme Josse; Cécile Batailler; Christian Chidiac; Mathieu Medina; S Lustig; Frédéric Laurent
Journal:  Open Forum Infect Dis       Date:  2018-10-24       Impact factor: 3.835

4.  Pharmacokinetic/Pharmacodynamic Dosage Individualization of Suppressive Beta-Lactam Therapy Administered by Subcutaneous Route in Patients With Prosthetic Joint Infection.

Authors:  Sylvain Goutelle; Anne Conrad; Cécile Pouderoux; Evelyne Braun; Frédéric Laurent; Marie-Claude Gagnieu; Sabine Cohen; Jérôme Guitton; Florent Valour; Tristan Ferry
Journal:  Front Med (Lausanne)       Date:  2021-03-31

5.  Long-Term Impact of Suppressive Antibiotic Therapy on Intestinal Microbiota.

Authors:  Rosa Escudero-Sánchez; Manuel Ponce-Alonso; Hugo Barragán-Prada; María Isabel Morosini; Rafael Cantón; Javier Cobo; Rosa Del Campo
Journal:  Genes (Basel)       Date:  2020-12-30       Impact factor: 4.096

6.  Outcomes of Second-stage Reimplantation After Modular Knee Arthrodesis for Periprosthetic Joint Infection.

Authors:  Alexandra Stavrakis; Erik N Mayer; Sai Devana; Madhav Chowdhry; Matthew Dipane; Edward McPherson
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-08-11

7.  Safety of Tedizolid as Suppressive Antimicrobial Therapy for Patients With Complex Implant-Associated Bone and Joint Infection due to Multidrug-Resistant Gram-Positive Pathogens: Results From the TediSAT Cohort Study.

Authors:  Tristan Ferry; Anne Conrad; Eric Senneville; Sandrine Roux; Céline Dupieux-Chabert; Aurélien Dinh; Sébastien Lustig; Sylvain Goutelle; Thomas Briot; Truong-Thanh Pham; Florent Valour
Journal:  Open Forum Infect Dis       Date:  2021-07-02       Impact factor: 3.835

8.  Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection.

Authors:  Tristan Ferry; Cécile Batailler; Anne Conrad; Claire Triffault-Fillit; Frédéric Laurent; Florent Valour; Christian Chidiac
Journal:  Open Forum Infect Dis       Date:  2018-09-25       Impact factor: 3.835

9.  Chronic prosthetic joint infections with a draining sinus. Who should receive suppressive antibiotic treatment?

Authors:  Karel-Jan Lensen; Rosa Escudero-Sanchez; Javier Cobo; Alex Soriano; Marjan Wouthuyzen-Bakker
Journal:  J Bone Jt Infect       Date:  2020-10-30

10.  Local antibiotic treatment with calcium sulfate as carrier material improves the outcome of debridement, antibiotics, and implant retention procedures for periprosthetic joint infections after hip arthroplasty - a retrospective study.

Authors:  Katharina Reinisch; Michel Schläppi; Christoph Meier; Peter Wahl
Journal:  J Bone Jt Infect       Date:  2022-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.